Evidence map›Paper›PMID 41275010›Full record

ReviewCommunications biology2025

The pursuit of ultrasensitive phosphoproteomics to unravel signalling in rare cells.

Emily J Gaizley, Silvia Surinova

Abstract readReview
In one paragraph

Review in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Emily J GaizleyUCL Cancer Institute, University College London, London, UK.ORCID http://orcid.org/0000-0003-0122-552X
Silvia SurinovaUCL Cancer Institute, University College London, London, UK. s.surinova@ucl.ac.uk.ORCID http://orcid.org/0000-0003-0442-9595

Funding

Cancer Research UK (CRUK) A31279Cancer Research UK (CRUK) CTRQQR-2021\100004C416/A25145
6 · The paper itself

Abstract

Mass spectrometry-based phosphoproteomic workflows enable routine study of signalling dynamics in contexts where cells are abundant. However, the analysis of cell signalling governed by phosphorylation requires an additional enrichment step which poses a significant challenge when dealing with limited material. The development of sensitive techniques that allow phosphoproteomic analysis of a few hundred cells is increasingly enabling researchers to disambiguate the complexity of protein signalling networks within heterogeneous cell populations. The imminent task at hand is to apply these techniques in research contexts guided by the available biological material to address complex questions about cellular function. Examples range from characterising differential treatment responses in distinct cell populations to investigating rare cell types from primary patient material or in vivo models. To achieve this, adapted protocols need to consider appropriate isolation of specific cells, simplified sample processing to avoid losses, labelling and multiplexing, and optimised analytical methodologies. Here, we discuss these aspects of the workflow, highlighting how innovations from low-input and single-cell proteomics can be adapted to drive low-input phosphoproteomics forward.

Indexed as

PhosphoproteinsProteomicsSignal TransductionAnimalsHumansMass SpectrometryPhosphorylationSingle-Cell AnalysisPhosphoproteins

Identifiers

PMID41275010
PMCPMC12673093

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.